Evaluating Patient-Centered Outcomes in the Randomized Controlled Trial and Beyond: Informing the Future with Lessons from the Past

被引:19
作者
Booth, Christopher M. [1 ]
机构
[1] Queens Univ, Canc Res Inst, Kingston, ON K7L 3N6, Canada
关键词
CELL LUNG-CANCER; METASTATIC BREAST-CANCER; MONITORING CLINICAL-TRIALS; VINORELBINE PLUS CISPLATIN; DISEASE-FREE SURVIVAL; FIRST-LINE THERAPY; COLORECTAL-CANCER; PHASE-III; POSTMENOPAUSAL WOMEN; 1ST-LINE THERAPY;
D O I
10.1158/1078-0432.CCR-10-1962
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In the era of molecular oncology, patients still define a useful therapy as one that allows them to live longer and helps them to live better. Although patient outcomes have clearly improved as a result of randomized controlled trials (RCT), it is critical that contemporary trials retain the perspective of these fundamental patient-centered outcomes. Trends in study design, results, and interpretation of oncology RCTs from the past provide a useful framework in which to consider how the research community may approach trial design in the future. Although the RCT remains the standard for establishing efficacy, this article also considers how population-based outcome studies can provide insight into effectiveness of new therapies and explores how the results of RCTs translate into benefit in the general population. Clin Cancer Res; 16(24); 5963-71. (C) 2010 AACR.
引用
收藏
页码:5963 / 5971
页数:9
相关论文
共 63 条
[1]  
[Anonymous], 2008, Cancer Facts Figures 2008
[2]  
[Anonymous], NCI ISS CLIN ANN CER
[3]   In defense of pharmacoepidemiology - Embracing the yin and yan of drug research [J].
Avorn, Jerry .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (22) :2219-2221
[4]   Clinical trial endpoints in ovarian cancer: Report of an FDA/ASCO/AACR public workshop [J].
Bast, Robert C. ;
Thigpen, J. Tate ;
Arbuck, Susan G. ;
Basen-Engquist, Karen ;
Burke, Laurie B. ;
Freedman, Ralph ;
Horning, Sandra J. ;
Ozols, Robert ;
Rustin, Gordon J. ;
Spriggs, David ;
Wenzel, Lari B. ;
Pazdur, Richard .
GYNECOLOGIC ONCOLOGY, 2007, 107 (02) :173-176
[5]   The Transition From Phase II To Phase III Studies [J].
Berthold, Dominik R. ;
Gulamhusein, Aliya ;
Jackson, John I. ;
Tannock, Ian F. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (07) :1150-1151
[6]   Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women:: Results of the tamoxifen or arimidex randomized group efficacy and tolerability study [J].
Bonneterre, J ;
Thürlimann, B ;
Robertson, JFR ;
Krzakowski, M ;
Mauriac, L ;
Koralewski, P ;
Vergote, I ;
Webster, A ;
Steinberg, M ;
von Euler, M .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (22) :3748-3757
[7]   Translating New Medical Therapies Into Societal Benefit The Role of Population-Based Outcome Studies [J].
Booth, Christopher M. ;
Mackillop, William J. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 300 (18) :2177-2179
[8]   Adoption of Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer: A Population-Based Outcomes Study [J].
Booth, Christopher M. ;
Shepherd, Frances A. ;
Peng, Yingwei ;
Darling, Gail E. ;
Li, Gavin ;
Kong, Weidong ;
Mackillop, William J. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (21) :3472-3478
[9]   Evolution of the Randomized Controlled Trial in Oncology Over Three Decades [J].
Booth, Christopher M. ;
Cescon, David W. ;
Wang, Lisa ;
Tannock, Ian F. ;
Krzyzanowska, Monika K. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (33) :5458-5464
[10]   Presentation of Nonfinal Results of Randomized Controlled Trials at Major Oncology Meetings [J].
Booth, Christopher M. ;
Le Maitre, Aurelie ;
Ding, Keyue ;
Farn, Kristen ;
Fralick, Michael ;
Phillips, Cameron ;
Cescon, David W. ;
Meyer, Ralph M. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (24) :3938-3944